XML 53 R31.htm IDEA: XBRL DOCUMENT
v3.25.4

Other Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | Net product sales by product were as follows (in millions):
|  | Years Ended December 31,
|  | 2025 |  | 2024 |  | 2023
COVID(1) |  | $ | 1,810 |  |  | $ | 3,084 |  |  | $ | 6,671 |
RSV |  | 8 |  |  | 25 |  |  | — |
Total |  | $ | 1,818 |  |  | $ | 3,109 |  |  | $ | 6,671 |
_______ (1)Includes sales of Spikevax and mNEXSPIKE. The following table summarizes product sales provision for the periods presented (in millions):
|  |  |  | Years Ended December 31,
|  |  |  |  |  | 2025 |  | 2024 |  | 2023
Gross product sales |  |  |  |  |  | $ | 3,304 |  |  | $ | 4,517 |  |  | $ | 8,203 |
Product sales provision: |  |  |  |  |  |  |  |  |  |
Wholesaler chargebacks, discounts and fees |  |  |  |  |  | (1,037) |  |  | (1,141) |  |  | (976) |
Returns, rebates and other fees (1) |  |  |  |  |  | (449) |  |  | (267) |  |  | (556) |
Total product sales provision |  |  |  |  |  | $ | (1,486) |  |  | $ | (1,408) |  |  | $ | (1,532) |
Net product sales |  |  |  |  |  | $ | 1,818 |  |  | $ | 3,109 |  |  | $ | 6,671 |
_______ (1)Includes an adjustment of approximately $216 million in 2024, reflecting a reduction in prior year provision estimates, primarily related to returns and chargebacks for the previous COVID vaccine season. Adjustments recorded in 2025 related to prior year provision estimates were not material. The following table summarizes other revenue for the periods presented (in millions):
|  |  |  | Years Ended December 31,
|  |  |  |  |  | 2025 |  | 2024 |  | 2023
Grant revenue |  |  |  |  |  | $ | 22 |  |  | $ | 37 |  |  | $ | 94 |
Collaboration revenue (Note 5) |  |  |  |  |  | 13 |  |  | 48 |  |  | 83 |
Licensing and royalty revenue |  |  |  |  |  | 11 |  |  | 42 |  |  | — |
Stand-ready manufacturing revenue |  |  |  |  |  | 80 |  |  | $ | — |  |  | $ | — |
Total other revenue |  |  |  |  |  | $ | 126 |  |  | $ | 127 |  |  | $ | 177 |
The following table summarizes grant revenue for the periods presented (in millions):
| Years Ended December 31,
| 2025 |  | 2024 |  | 2023
BARDA | $ | 9 |  |  | $ | 34 |  |  | $ | 88 |
Other grant revenue | 13 |  |  | 3 |  |  | 6 |
Total grant revenue | $ | 22 |  |  | $ | 37 |  |  | $ | 94 |
The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):
|  | Years Ended December 31,
Collaboration Revenue by Strategic Collaborator: |  | 2025 |  | 2024 |  | 2023
Vertex |  | $ | 13 |  |  | $ | 23 |  |  | $ | 82 |
Other |  | — |  |  | 25 |  |  | 1 |
Total collaboration revenue |  | $ | 13 |  |  | $ | 48 |  |  | $ | 83 |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration